RecruitingPhase 3NCT06952803

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Studying Multiple endocrine neoplasia

Last synced from ClinicalTrials.gov May 13, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Intervention: Saruparib(drug)
Enrollment: 700 enrolled
Eligibility: 18 years · MALE
Timeline: 2025 – 2036

Study locations (30)

Research Site, Phoenix, Arizona, United States
Research Site, Tucson, Arizona, United States
Research Site, La Jolla, California, United States
Research Site, Los Angeles, California, United States
Research Site, San Diego, California, United States
Research Site, San Luis Obispo, California, United States
Research Site, Lakewood, Colorado, United States
Research Site, Hialeah, Florida, United States
Research Site, Jacksonville, Florida, United States
Research Site, Tampa, Florida, United States
Research Site, Newnan, Georgia, United States
Research Site, Chicago, Illinois, United States
Research Site, Chicago Ridge, Illinois, United States
Research Site, Greenwood, Indiana, United States
Research Site, Jeffersonville, Indiana, United States
+15 more locations on ClinicalTrials.gov

Collaborators

Parexel

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06952803 on ClinicalTrials.gov

Other trials for Multiple endocrine neoplasia

Additional recruiting or active studies for the same condition.

See all trials for Multiple endocrine neoplasia →

← Back to all trials